Previous Article | Next Article 
Journal of Virology, December 2007, p. 13346-13353, Vol. 81, No. 24
0022-538X/07/$08.00+0 doi:10.1128/JVI.01361-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1
Eri Miyagi,
Sandrine Opi,
Hiroaki Takeuchi,
Mohammad Khan,
Ritu Goila-Gaur,
Sandra Kao, and
Klaus Strebel*
Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892-0460
Received 22 June 2007/
Accepted 30 September 2007
APOBEC3G (APO3G) is a cellular cytidine deaminase with potent antiviral activity. Initial studies of the function of APO3G demonstrated extensive mutation of the viral genome, suggesting a model in which APO3G's antiviral activity is due to hypermutation of the viral genome. Recent studies, however, found that deaminase-defective APO3G mutants transiently expressed in virus-producing cells exhibited significant antiviral activity, suggesting that the antiviral activity of APO3G could be dissociated from its deaminase activity. To directly compare the antiviral activities of wild-type (wt) and deaminase-defective APO3G, we used two approaches: (i) we titrated wt and deaminase-defective APO3G in transient-transfection studies to achieve similar levels of virus-associated APO3G and (ii) we constructed stable cell lines and selected clones expressing comparable amounts of wt and deaminase-defective APO3G. Viruses produced under these conditions were tested for viral infectivity. The results from the two approaches were consistent and suggested that the antiviral activity of deaminase-defective APO3G was significantly lower than that of wt APO3G. We conclude that efficient inhibition of vif-defective human immunodeficiency virus type 1 requires catalytically active APO3G.
* Corresponding author. Mailing address: Viral Biochemistry Section, Laboratory of Molecular Microbiology, NIAID, NIH, Bldg. 4, Room 310, 4 Center Drive, MSC 0460, Bethesda, MD 20892-0460. Phone: (301) 496-3132. Fax: (301) 402-0226. E-mail:
kstrebel{at}nih.gov
Published ahead of print on 10 October 2007.
These authors equally contributed to this work.
Journal of Virology, December 2007, p. 13346-13353, Vol. 81, No. 24
0022-538X/07/$08.00+0 doi:10.1128/JVI.01361-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Iwatani, Y., Chan, D. S. B., Liu, L., Yoshii, H., Shibata, J., Yamamoto, N., Levin, J. G., Gronenborn, A. M., Sugiura, W.
(2009). HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl. Acad. Sci. USA
106: 19539-19544
[Abstract]
[Full Text]
-
Chen, G., He, Z., Wang, T., Xu, R., Yu, X.-F.
(2009). A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G. J. Virol.
83: 8674-8682
[Abstract]
[Full Text]
-
Piantadosi, A., Humes, D., Chohan, B., McClelland, R. S., Overbaugh, J.
(2009). Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif. J. Virol.
83: 7805-7814
[Abstract]
[Full Text]
-
Zielonka, J., Bravo, I. G., Marino, D., Conrad, E., Perkovic, M., Battenberg, M., Cichutek, K., Munk, C.
(2009). Restriction of Equine Infectious Anemia Virus by Equine APOBEC3 Cytidine Deaminases. J. Virol.
83: 7547-7559
[Abstract]
[Full Text]
-
Henriet, S., Mercenne, G., Bernacchi, S., Paillart, J.-C., Marquet, R.
(2009). Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors. Microbiol. Mol. Biol. Rev.
73: 211-232
[Abstract]
[Full Text]
-
Green, L. A., Liu, Y., He, J. J.
(2009). Inhibition of HIV-1 Infection and Replication by Enhancing Viral Incorporation of Innate Anti-HIV-1 Protein A3G: A NON-PATHOGENIC Nef MUTANT-BASED ANTI-HIV STRATEGY. J. Biol. Chem.
284: 13363-13372
[Abstract]
[Full Text]
-
MacDuff, D. A., Demorest, Z. L., Harris, R. S.
(2009). AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Res
37: 1854-1867
[Abstract]
[Full Text]
-
Malim, M. H
(2009). APOBEC proteins and intrinsic resistance to HIV-1 infection. Phil Trans R Soc B
364: 675-687
[Abstract]
[Full Text]
-
Pery, E., Rajendran, K. S., Brazier, A. J., Gabuzda, D.
(2009). Regulation of APOBEC3 Proteins by a Novel YXXL Motif in Human Immunodeficiency Virus Type 1 Vif and Simian Immunodeficiency Virus SIVagm Vif. J. Virol.
83: 2374-2381
[Abstract]
[Full Text]
-
Khatua, A. K., Taylor, H. E., Hildreth, J. E. K., Popik, W.
(2009). Exosomes Packaging APOBEC3G Confer Human Immunodeficiency Virus Resistance to Recipient Cells. J. Virol.
83: 512-521
[Abstract]
[Full Text]
-
Goila-Gaur, R., Khan, M. A., Miyagi, E., Strebel, K.
(2009). Differential Sensitivity of "Old" versus "New" APOBEC3G to Human Immunodeficiency Virus Type 1 Vif. J. Virol.
83: 1156-1160
[Abstract]
[Full Text]
-
Tan, L., Sarkis, P. T. N., Wang, T., Tian, C., Yu, X.-F.
(2009). Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J.
23: 279-287
[Abstract]
[Full Text]
-
Ikeda, T., Ohsugi, T., Kimura, T., Matsushita, S., Maeda, Y., Harada, S., Koito, A.
(2008). The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res
36: 6859-6871
[Abstract]
[Full Text]
-
Bogerd, H. P., Tallmadge, R. L., Oaks, J. L., Carpenter, S., Cullen, B. R.
(2008). Equine Infectious Anemia Virus Resists the Antiretroviral Activity of Equine APOBEC3 Proteins through a Packaging-Independent Mechanism. J. Virol.
82: 11889-11901
[Abstract]
[Full Text]
-
Kawada, M., Tsukamoto, T., Yamamoto, H., Iwamoto, N., Kurihara, K., Takeda, A., Moriya, C., Takeuchi, H., Akari, H., Matano, T.
(2008). Gag-Specific Cytotoxic T-Lymphocyte-Based Control of Primary Simian Immunodeficiency Virus Replication in a Vaccine Trial. J. Virol.
82: 10199-10206
[Abstract]
[Full Text]
-
Armitage, A. E., Katzourakis, A., de Oliveira, T., Welch, J. J., Belshaw, R., Bishop, K. N., Kramer, B., McMichael, A. J., Rambaut, A., Iversen, A. K. N.
(2008). Conserved Footprints of APOBEC3G on Hypermutated Human Immunodeficiency Virus Type 1 and Human Endogenous Retrovirus HERV-K(HML2) Sequences. J. Virol.
82: 8743-8761
[Abstract]
[Full Text]
-
Land, A. M., Ball, T. B., Luo, M., Pilon, R., Sandstrom, P., Embree, J. E., Wachihi, C., Kimani, J., Plummer, F. A.
(2008). Human Immunodeficiency Virus (HIV) Type 1 Proviral Hypermutation Correlates with CD4 Count in HIV-Infected Women from Kenya. J. Virol.
82: 8172-8182
[Abstract]
[Full Text]
-
Bogerd, H. P., Cullen, B. R.
(2008). Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA
14: 1228-1236
[Abstract]
[Full Text]
-
Chelico, L., Sacho, E. J., Erie, D. A., Goodman, M. F.
(2008). A Model for Oligomeric Regulation of APOBEC3G Cytosine Deaminase-dependent Restriction of HIV. J. Biol. Chem.
283: 13780-13791
[Abstract]
[Full Text]
-
Langlois, M.-A., Neuberger, M. S.
(2008). Human APOBEC3G Can Restrict Retroviral Infection in Avian Cells and Acts Independently of both UNG and SMUG1. J. Virol.
82: 4660-4664
[Abstract]
[Full Text]
-
Mulder, L. C. F., Harari, A., Simon, V.
(2008). Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. USA
105: 5501-5506
[Abstract]
[Full Text]
-
Aguiar, R. S., Lovsin, N., Tanuri, A., Peterlin, B. M.
(2008). Vpr.A3A Chimera Inhibits HIV Replication. J. Biol. Chem.
283: 2518-2525
[Abstract]
[Full Text]